Clinical Impact of High-Sensitivity Cardiac Troponin T Implementation in the Community.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
29 06 2021
Historique:
received: 04 03 2021
revised: 19 04 2021
accepted: 21 04 2021
entrez: 25 6 2021
pubmed: 26 6 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Limited U.S. data exist regarding high-sensitivity cardiac troponin (cTn) implementation. This study sought to evaluate the impact of high-sensitivity cardiac troponin T (cTnT) implementation. Observational U.S. cohort study of emergency department (ED) patients undergoing measurement of cTnT during the transition from 4th (pre-implementation March 12, 2018, to September 11, 2018) to 5th generation (Gen) cTnT (post-implementation September 12, 2018, to March 11, 2019). Diagnoses were adjudicated following the Fourth Universal Definition of Myocardial Infarction (MI). Resources evaluated included length of stay, hospitalizations, and cardiac testing. In this study, 3,536 unique patients were evaluated, including 2,069 and 2,491 ED encounters pre- and post-implementation. Compared with 4th Gen cTnT, encounters with ≥1 cTnT >99th percentile increased using 5th Gen cTnT (15% vs. 47%; p < 0.0001). Acute MI (3.3% vs. 8.1%; p < 0.0001) and myocardial injury (11% vs. 38%; p < 0.0001) increased. Although type 1 MIs increased (1.7% vs. 2.9%; p = 0.0097), the overall MI increase was largely due to more type 2 MIs (1.6% vs. 5.2%; p < 0.0001). Women were less likely than men to have MI using 4th Gen cTnT (2.3% vs. 4.4%; p = 0.008) but not 5th Gen cTnT (7.7% vs. 8.5%; p = 0.46). Overall length of stay and stress testing were reduced, and angiography was increased (all p < 0.05). Among those without cTnT increases, there were more ED discharges and a reduction in length of stay, echocardiography, and stress tests (all p < 0.05). High-sensitivity cTnT implementation resulted in a marked increase in myocardial injury and MI, particularly in women and patients with type 2 MI. Despite this, except for angiography, overall resource use did not increase. Among those without cTnT increases, there were more ED discharges and fewer cardiac tests.

Sections du résumé

BACKGROUND
Limited U.S. data exist regarding high-sensitivity cardiac troponin (cTn) implementation.
OBJECTIVES
This study sought to evaluate the impact of high-sensitivity cardiac troponin T (cTnT) implementation.
METHODS
Observational U.S. cohort study of emergency department (ED) patients undergoing measurement of cTnT during the transition from 4th (pre-implementation March 12, 2018, to September 11, 2018) to 5th generation (Gen) cTnT (post-implementation September 12, 2018, to March 11, 2019). Diagnoses were adjudicated following the Fourth Universal Definition of Myocardial Infarction (MI). Resources evaluated included length of stay, hospitalizations, and cardiac testing.
RESULTS
In this study, 3,536 unique patients were evaluated, including 2,069 and 2,491 ED encounters pre- and post-implementation. Compared with 4th Gen cTnT, encounters with ≥1 cTnT >99th percentile increased using 5th Gen cTnT (15% vs. 47%; p < 0.0001). Acute MI (3.3% vs. 8.1%; p < 0.0001) and myocardial injury (11% vs. 38%; p < 0.0001) increased. Although type 1 MIs increased (1.7% vs. 2.9%; p = 0.0097), the overall MI increase was largely due to more type 2 MIs (1.6% vs. 5.2%; p < 0.0001). Women were less likely than men to have MI using 4th Gen cTnT (2.3% vs. 4.4%; p = 0.008) but not 5th Gen cTnT (7.7% vs. 8.5%; p = 0.46). Overall length of stay and stress testing were reduced, and angiography was increased (all p < 0.05). Among those without cTnT increases, there were more ED discharges and a reduction in length of stay, echocardiography, and stress tests (all p < 0.05).
CONCLUSIONS
High-sensitivity cTnT implementation resulted in a marked increase in myocardial injury and MI, particularly in women and patients with type 2 MI. Despite this, except for angiography, overall resource use did not increase. Among those without cTnT increases, there were more ED discharges and fewer cardiac tests.

Identifiants

pubmed: 34167641
pii: S0735-1097(21)04820-8
doi: 10.1016/j.jacc.2021.04.050
pmc: PMC9090513
pii:
doi:

Substances chimiques

Troponin T 0

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3160-3170

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002377
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures This publication was made possible in part by the Mayo Clinic CTSA through grant UL1TR002377 from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health. Dr. Jaffe has consulted or presently consults for most of the major diagnostics companies, including Beckman, Abbott, Siemens, ET Healthcare, Roche, Radiometer, Sphingotec, Amgen, and Novartis. Dr. Sandoval has previously served on the Advisory Boards for Roche Diagnostics and Abbott Diagnostics without personal compensation; and has also been a speaker without personal financial compensation for Abbott Diagnostics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Olatunde Ola (O)

Division of Hospital Internal Medicine, Mayo Clinic Health System, La Crosse, Wisconsin, USA; Center for Clinical and Translational Science, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA.

Ashok Akula (A)

Division of Hospital Internal Medicine, Mayo Clinic Health System, La Crosse, Wisconsin, USA; Center for Clinical and Translational Science, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA.

Laura De Michieli (L)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA; Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padova, Italy.

Marshall Dworak (M)

Department of Cardiovascular Diseases, Mayo Clinic Health System, La Crosse, Wisconsin, USA.

Erika Crockford (E)

Department of Family Medicine, Mayo Clinic Health System, La Crosse, Wisconsin, USA.

Ronstan Lobo (R)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Nicholas Rastas (N)

Department of Cardiovascular Diseases, Mayo Clinic Health System, La Crosse, Wisconsin, USA.

Jonathan D Knott (JD)

Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Ramila A Mehta (RA)

Department of Health Sciences Research, Mayo College of Medicine, Rochester, Minnesota, USA.

David O Hodge (DO)

Department of Health Sciences Research, Mayo College of Medicine, Jacksonville, Florida, USA.

Eric Grube (E)

Department of Emergency Medicine, Mayo Clinic Health System, La Crosse, Wisconsin, USA.

Swetha Karturi (S)

Division of Hospital Internal Medicine, Mayo Clinic Health System, La Crosse, Wisconsin, USA.

Scott Wohlrab (S)

Department of Laboratory Medicine and Pathology, Mayo Clinic Health System, La Crosse, Wisconsin, USA.

Tahir Tak (T)

Department of Cardiovascular Diseases, Mayo Clinic Health System, La Crosse, Wisconsin, USA.

Charles Cagin (C)

Department of Cardiovascular Diseases, Mayo Clinic Health System, La Crosse, Wisconsin, USA.

Rajiv Gulati (R)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.

Allan S Jaffe (AS)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Yader Sandoval (Y)

Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: sandoval.yader@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH